Oxyphenbutazone Anhydrous

CHEMBL1228 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
324.4 g/mol
LogP
2.7
Phase
4

An anhydrous form of oxyphenbutazone, sharing the same therapeutic uses.

分子量

324.4000 g/mol

LogP

2.70

TPSA

60.90 Ų

リピンスキーの五則

適合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O

InChI

InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3

Molecular Formula

C19H20N2O3

HBD / HBA

1 / 3

回転可能結合数

5

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An anhydrous form of oxyphenbutazone, sharing the same therapeutic uses.

Yes, Oxyphenbutazone Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1228. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4641. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.